Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Market Movers
TipRanks 50 Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
The Fly
Avidity, Phathom mentioned as potential takeout targets at Needham
3d ago
BMY
NVO
Premium
The Fly
Keros Therapeutics announces first patient dosed in Phase 3 RENEW trial
3d ago
TAK
KROS
Premium
Ratings
Buy Rating for Takeda Pharmaceutical Driven by Successful Phase 3 Trials of Oveporexton
5d ago
TAK
Premium
The Fly
Morning Movers: Sonnet BioTherapeutics skyrockets after $888M combination
6d ago
AZN
TAK
Premium
The Fly
Takeda announces oveporexton studies met all primary, secondary endpoints
6d ago
TAK
Premium
Company Announcements
Takeda’s Oveporexton Shows Promise in Phase 3 Narcolepsy Studies
6d ago
Premium
Company Announcements
Takeda Completes Treasury Share Disposal with Minor Adjustments
12d ago
Premium
The Fly
Takeda announces FDA approval of Gammagard Liquid ERC
20d ago
TAK
Premium
Company Announcements
Takeda Announces New Director Assignments, Emphasizing Strong Governance
25d ago
Premium
Company Announcements
Takeda Announces Disposal of Treasury Shares for Global Employee Incentive Plan
1M ago
Premium
The Fly
Takeda reports EC approves Adcetris combination for Hodgkin lymphoma
2M ago
TAK
Premium
Ratings
Positive Outlook for Takeda Pharmaceutical Co: Buy Rating Supported by Promising Phase 3 Data and Projected Sales for Rusfertide
2M ago
TAK
Premium
Company Announcements
Takeda Announces New Shelf Registration for LTIP Support
2M ago
Premium
Company Announcements
Takeda and Protagonist Reveal Positive Phase 3 VERIFY Study Results
2M ago
Premium
The Fly
Protagonist, Takeda announces Phase 3 VERIFY study met primary endpoint
2M ago
TAK
PTGX
Premium
The Fly
Veeva price target raised to $300 from $270 at Needham
2M ago
CRM
TAK
Premium
Ratings
Takeda Pharmaceutical Co: Balancing Challenges and Opportunities Amid US Tariffs and Pricing Uncertainties
2M ago
TAK
Premium
Ratings
Takeda Pharmaceutical: Resilient Growth and Strong Sales Ambition Justify Buy Rating
2M ago
TAK
Premium
The Fly
Veeva has ‘meaningful’ Life Science head start over Salesforce, says Oppenheimer
2M ago
CRM
TAK
Premium
The Fly
Takeda publishes oveporexton data in New England Journal of Medicine
2M ago
TAK
Premium
Company Announcements
Takeda Pharmaceutical Reports Revenue Growth Amid Profit Decline
2M ago
Premium
Company Announcements
Takeda Continues Stock Compensation Plans for Directors and Management
2M ago
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
